We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Surge Expected in Personal Flow Cytometry Market

By LabMedica International staff writers
Posted on 17 Feb 2011
The use of flow cytometers in biotech research laboratories should get a boost after the acquisition of a pioneer manufacturer of personal flow cytometers by one of the major international medical technology companies.

Flow cytometry is a method of sorting and measuring types of cells by fluorescent labeling of markers on the surface of the cells. More...
Accuri Cytometers, Inc. (Ann Arbor, MI, USA) was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their laboratory. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument.

Accuri Cytometers developed the C6, a system so easy to operate and maintain that a dedicated operator is not required. New C6 users can be trained in less than 30 minutes. The C6 employs laboratory-grade water for sheath fluid so commercial sheath fluids are not needed. Maintenance is made simple with automatic rinse and decontamination upon instrument shutdown. No room renovations are required to install a C6, since it fits easily on the benchtop and uses standard electrical connections. The C6 is small enough to fit into every lab and can even be placed in a laminar flow hood

To secure a firm place at the head of the flow cytometry parade, Becton, Dickinson and Company (BD) (Franklin Lakes, NJ, USA) has acquired Accuri Cytometers. BD is a global medical technology company that is focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, and advancing drug discovery. BD develops, manufactures, and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products. It serves healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry.

The acquisition is subject to regulatory approvals and is expected to close during the third quarter of fiscal year 2011.

"Making flow cytometry more accessible to a wider audience of scientists and clinicians is one aspect of our cell analysis growth strategy,” said William Rhodes, president of BD Biosciences. "With its small footprint, ease of use and affordable price, the Accuri flow cytometer enables the adoption of flow cytometry by a broad range of researchers whom BD does not currently serve.”

Related Links:
Accuri Cytometers, Inc.
Becton, Dickinson and Company (BD)




New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.